Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N5LJ
|
|||
| Former ID |
DNC000782
|
|||
| Drug Name |
Igmesine
|
|||
| Synonyms |
Igmesine hydrochloride; JO-1784; UNII-JV6M14TY35; Igmesine Hydrochloride [USAN]; 130152-35-1; Cinnamyl-1-phenyl-1-N-methyl-N-cyclopropylene; JO 1784; CI 1019; CI-1019; JV6M14TY35; (+)-alpha-(E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; (+)-Igmesine hydrochloride; (+)-(E)-N-(Cyclopropylmethyl)-alpha-ethyl-N-methyl-alpha-(3-phenyl-2-propenyl)benzenemethanamine hydrochloride; Igmesine hydrochloride (USAN); (+)-alpha-((E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; Alphagen
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Phase 2 | [1] | |
| Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 1 | [2] | ||
| Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9] | Phase 1 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H29N
|
|||
| Canonical SMILES |
CCC(CC=CC1=CC=CC=C1)(C2=CC=CC=C2)N(C)CC3CC3
|
|||
| InChI |
1S/C23H29N/c1-3-23(22-14-8-5-9-15-22,24(2)19-21-16-17-21)18-10-13-20-11-6-4-7-12-20/h4-15,21H,3,16-19H2,1-2H3/b13-10+
|
|||
| InChIKey |
VCZSWYIFCKGTJI-JLHYYAGUSA-N
|
|||
| CAS Number |
CAS 140850-73-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-1-antitrypsin (SERPINA1) | Target Info | Modulator | [2] |
| Opioid receptor sigma 1 (OPRS1) | Target Info | Agonist | [3], [4], [5] | |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | IL6 Signaling Pathway | |||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| FOXA1 transcription factor network | ||||
| Reactome | Platelet degranulation | |||
| COPII (Coat Protein 2) Mediated Vesicle Transport | ||||
| Cargo concentration in the ER | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001429) | |||
| REF 2 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | |||
| REF 3 | Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19. | |||
| REF 4 | Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs. 2004;18(5):269-84. | |||
| REF 5 | Strain differences in sigma(1) receptor-mediated behaviours are related to neurosteroid levels. Eur J Neurosci. 2002 May;15(9):1523-34. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.